Content Conference Coverage Conferences AASLD2017
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: Hepatitis B
- Created on Thursday, 30 November 2017 00:00
HIVandHepatitis.com coverage of the 2017 Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases, AASLD), October 20-24, 2017, in Washington, DC.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Created on Thursday, 30 November 2017 00:00
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: REP 2139 Combination Therapy Leads to Functional Control of Hepatitis B Virus
- Details
- Category: HBV Treatment
- Created on Thursday, 30 November 2017 00:00
A majority of chronic hepatitis B patients treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve "functional control" of hepatitis B virus (HBV), according to a late-breaking poster presentation at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Created on Thursday, 30 November 2017 00:00
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Created on Thursday, 30 November 2017 00:00
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/30/17
More Articles...
- AASLD 2017: Treatment that Interferes with Viral Assembly Shows Promise for Hepatitis B
- AASLD 2017: RNA Interference Therapy Lowers Viral Biomarker in People with Hepatitis B
- AASLD 2017: Immune Modulator Inarigivir Looks Promising for Hepatitis B
- U.S. Approves New Hepatitis B Vaccine as Public Health Agencies Update Guidelines
- AASLD 2017: Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
- AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C Worldwide
- AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
- AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
- AASLD 2017: Model Shows Hepatitis C Treatment is Cost-Effective in Japan
- AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life
- AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis
- AASLD 2017: Hepatitis C Testing Linked to Reduced Opioid Use
- AASLD 2017: HCV Infections Are Rising Among HIV+ Gay Men In San Diego
- AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study
- AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
- AASLD 2017: Women with Fatty Liver Disease at Higher Risk for Heart Disease
- AASLD 2017: Experimental NASH Therapy Improves Liver Fat and Fibrosis
Web Design and Development by